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We describe a case of a 67-year-old Caucasian woman with an early, moderately-diﬀerentiated adenocarcinoma of the
endometrium.Alevonorgestrel-releasingintrauterinesystemwasinserted,whichshetoleratedwell.AfullD&C,followingremoval
of the device, was performed after 9 months, conﬁrming absence of tumoral tissue. Examination after 24 months showed a very
thin endometrium, indicating complete remission.
1.Introduction
An alternative route for the administration of progestins
is via the intrauterine one. Intrauterine progestin delivery,
in particular levonorgestrel (LNG), is much more eﬀective
in suppressing the endometrium than oral treatment. This
is due to the uniform suppression of the endometrium
throughout the whole thickness of the mucosa caused
by the high tissue concentrations when the hormone is
applied locally [1]. This form of treatment should, therefore,
be preferred over oral treatment for precancerous lesions
of the endometrium and early stage invasive endometrial
cancer. Surgery is nowadays still the method of choice for
the management of these lesions. However, many patients
are not eligible (unﬁt) for surgery and younger women
want to preserve their fertility. For these reasons, local
delivery of a potent progestin should be the alternative
method of choice in these women if it could be shown to
be eﬀective. An intrauterine system also provides optimal
patient compliance.
There are only a few reports in the literature which
demonstrate successful treatment of early stage endometrial
carcinoma with the LNG-releasing intrauterine system (IUS)
[2–5]. We present a case of a 67-year-old woman with
am o d e r a t e l yd i ﬀerentiated invasive adenocarcinoma of the
endometrium who was successfully treated with the LNG-
IUS.
2. Case Presentation
In May 2008, a 67-year-old woman residing in the United
States of America presented with a history of post-
menopausal bleeding since January 2008. She had been using
local estrogen treatment for vaginal dryness without any
systemic hormonal therapy. She had been diagnosed with an
endometrial carcinoma and was advised to undergo surgery.
As she wanted to avoid surgery, she sought an alternative
treatment and consulted DW. The clinical examination
was normal, with normal body weight, and a transvagi-
nal ultrasound scan showed normal appearance of the
myometrium and endometrium. An outpatient endometrial
pipelle biopsy was performed which revealed a moderately
diﬀerentiated adenocarcinoma (Figure 1) with minimal
myometrial invasion (Clinical FIGO stage I). An LNG-
IUS (Femilis, Contrel Research, Ghent, Belgium) releasing
20µg of LNG/d was inserted (Figure 2), and advice was
given to request a repeat biopsy within the next 3 to 6
months. Spotting continued for several weeks and then2 Obstetrics and Gynecology International
Figure 1: Endometrial curetting prior to therapy, irregular crib-
riform glands, and mild atypia: well-diﬀerentiated endometrioid
carcinoma (H&E 100x).
Figure 2: T-shaped Femilis LNG-IUS with 28mm long crossarm
and 3cm long and 2.4mm wide drug delivery compartment.
stopped. As the patient was completely free of symptoms 6
months after insertion of the LNG-IUS, a pelvic transvaginal
ultrasound was performed, including a 3D-ultrasound and
a Duplex Doppler with Color Flow Mapping. The uterus
appeared completely normal, and there was no evidence of
any pathology. The endometrium showed normal thickness,
and there was no evidence of any endometrial abnormality
or myometrial invasion (Figures 3 and 4). The LNG-IUS
was identiﬁed in situ, as expected. Three months later, in
order to ascertain complete remission, the LNG-IUS was
removed, and a full D&C was performed. The uterine sound
length was 6cm. The whole cavity was explored, and very
scant tissue was removed. Histological examination of the
specimen revealed a secretory endometrium without signs of
hyperplasia or atypia (Figure 5). A mini Femilis LNG-IUS
(crossarm 24mm long and 28mm long and 2.0 wide drug
compartment) was inserted as a precaution.
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Figure 3: Sonographic view of uterus with LNG-IUS in situ. The
endometrial thickness is 3.42mm.
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Figure 4: 3D-sonographic view of normal uterus (transverse
section) with LNG-IUS in center.
The patient was again examined two years following ini-
tialtreatment.Shehadnosymptoms,andvaginalultrasound
showed a very thin endometrium and normal position of the
LNG-IUS in the uterine cavity.
3. Comment
We previously reported on the successful management of
nonatypical and atypical endometrial hyperplasia with an
LNG-IUS [6, 7]. Endometrial cancer is a very common
disorder. Over 40,000 cases are diagnosed in the United
States annually with almost 75% of cases presenting with
FIGO stage I disease (Cancer fact & ﬁgures, 2004). The
underlying mechanism for the development of some types
of endometrial cancer is exogenous or endogenous hormone
stimulation [8]. Therefore, progesterone or progestin treat-
ment,bycounteractingtheeﬀectofestrogen,mayreversethe
neoplastic process. Levonorgestrel, delivered locally with a
drug delivery system, is probably the best choice as the tissue
concentrations are many times higher than when the hor-
mone is administered orally. “Progestasert,” a progesterone-
releasingIUS(AlzaCorp.,PaloAlto,CA),hasbeenusedwith
good results. However, a levonorgestrel-releasing IUS shouldObstetrics and Gynecology International 3
Figure 5: Endometrial curetting posttherapy, small regular glands
with tubal metaplasia, surrounded by decidualised stroma (H&E
100x).
b ep r e f e r r e da si ti sm u c hm o r ep o t e n t[ 9]. Histological
regressionofearlyendometrialcancerhasalsobeenobtained
with orally administered progestins but the results cannot
be expected to be as good as local treatment [10, 11]. In
addition,withanIUSthereislessriskofsystemicsideeﬀects,
often leading to poor compliance. Intrauterine delivery of
levonorgestrel causes a more uniform response throughout
the whole thickness of the endometrium, including the basal
layer, compared to intrauterine progesterone delivery or
orally administered progestins [12]. The Femilis, currently
still an experimental IUS, releases the same amount of LNG
as Mirena (BayerSchering Inc., Berlin, Germany) but the
initial release is approximately three times higher than the
release of LNG of Mirena during the ﬁrst weeks. This could
be advantageous as it increases the impact on the neoplastic
endometrial cells. It is possible that the fast remission in this
patient is due to the strong suppression of the endometrium
immediately after insertion of the LNG-IUS. Several cases of
endometrial carcinoma treated with an LNG-IUS (Mirena)
have been published [11, 13, 14]. The LNG-IUS should be
high up in the fundus to guarantee proper release of the
hormone in the fundal area of the uterus. We question if the
LNG-IUS was properly located in the uterine cavity in some
of these unsuccessful cases. A frameless LNG-IUS should be
preferredincaseofdisplacement,partialortotalexpulsionof
aframedLNG-IUS.ThisLNG-IUSisanchoredtotheuterine
fundus and is unlikely to become displaced or expelled [15].
We would also recommend to remain cautious in women
presenting with irregular bleeding after 6 to 12 months
following the insertion of an LNG-IUS and to evaluate the
endometrium thoroughly.
Evidently,thebestcandidatesforlocaltreatmentwiththe
LNG-IUS are those with no or only minimal endometrial
invasion. In these cases, the LNG-IUS could be the treatment
of choice especially in women with contraindications for
surgery, or even for older women. We agree with Bahamon-
des et al. that the intrauterine route should be preferred
over the oral route. Perhaps, the LNG-IUS, releasing 20µg
of LNG/d, or a higher dose, may be curative in a larger
proportion of women with early endometrial carcinoma.
Clearlyfurtherstudiesareneededtoelucidatethispossibility.
In the meantime, we can conclude that selected women
could beneﬁt from treatment with LNG-IUS but we should
keep in mind that continued observation is necessary as
the endometrial cells may preserve their neoplastic capacity.
Women who respond positively should remain protected
for years with a long-acting hormone-releasing intrauterine
system.
Condensation
Treatment of early endometrial carcinoma with LNG-IUS.
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